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Detection of 1p36 deletion by clinical exome-first diagnostic
approach
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Although chromosome 1p36 deletion syndrome is considered clinically recognizable based on characteristic features, the clinical
manifestations of patients during infancy are often not consistent with those observed later in life. We report a 4-month-old girl
who showed multiple congenital anomalies and developmental delay, but no clinical signs of syndromic disease caused by a
terminal deletion in 1p36.32-p36.33 that was first identified by targeted-exome sequencing for molecular diagnosis.
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Chromosome 1p36 deletion syndrome (MIM 607872) is the most
common terminal deletion syndrome in humans, occurring in
~ 1 in 5,000 individuals.1, 2 A pattern of characteristic functional
deficits, congenital anomalies and physical features associated
with 1p36 deletions has been observed in case reports, as well as
clinical descriptions of large cohorts of individuals with 1p36
deletions.2–7 Defining this pattern has made chromosome 1p36
deletion syndrome a clinically recognizable entity. A character-
istic facial appearance, hypotonia, psychomotor retardation and
poor or absent speech are suggestive of chromosome 1p36
deletion syndrome, and the diagnosis is confirmed by detecting
a deletion of the most distal band of the short arm of
chromosome 1. However, a relatively high proportion of
reported cases of chromosome 1p36 deletion syndrome have
been diagnosed after the age of 1 year because these
characteristics are often difficult to recognize during infancy,
and significant phenotypic variability is observed among
patients with this disease.2–7
Chromosomal microarray (CMA) is a powerful tool for detecting
genomic copy number aberrations. In 2010, CMA testing was
recommended as a first-tier examination for patients with
unexplained developmental delay/intellectual disability (DD),
autism spectrum disorders or multiple congenital anomalies.8
This diagnostic method is commonly used worldwide and can
detect all types of chromosomal alterations associated with
chromosome 1p36 deletion syndrome, such as terminal deletions,
interstitial deletions, complex rearrangements and derivative
chromosomes.3 CMA can be performed in the first-tier if patients
are suspected of having this disease based on their clinical
features. Recently, next-generation sequencing (NGS), particularly
whole-exome sequencing (WES) or targeted-exome sequencing
(TES), has become common worldwide as a clinical diagnostic tool
for patients with suspected mutations, such as single nucleotide
variations (SNVs) and small insertions/deletions (indels), that are
responsible for human single gene disorders. Pathogenic copy
number variations (CNVs), which frequently contain the genes that
are functionally responsible for phenotypes of diseases,9 in
targeted exons can also be simultaneously detected by WES and
TES, leading to an appropriate clinical diagnosis.10,11 Therefore, it
would be advantageous to screen genetic abnormalities using
WES/TES data before performing CMA in undiagnosed syndromic
patients suspected of having either single gene defects or cryptic
chromosomal aberrations.
Here, we present a 4-month-old patient with chromosome
1p36 deletion syndrome, which was not suspected from
clinical findings before genetic testing and was successfully
diagnosed by the NGS-first approach using a disease-related
exome panel.
The patient was a 4-month-old Japanese girl born to non-
consanguineous healthy parents aged 20 (father) and 17 years
(mother). Intrauterine growth retardation and ventricular septal
defect (VSD) were indicated via a 28-week antenatal ultrasound.
The child was born by artificial labor at 38 weeks and 3 days of
gestation owing to oligohydramnios detected via a 38-week
antenatal scan and had a birth weight of 1,718 g (−3.4 s.d.), a
length of 41.5 cm (−3.2 s.d.) and an occipitofrontal circumference
of 30 cm (−2.3 s.d.). Apgar scores were 9 and 10 at 1 and 5 min
after birth, respectively. The neonate was admitted to the neonatal
intensive care unit with polypnea that developed immediately
after birth, and subsequently required oxygenation. The patient
had multiple congenital heart defects, such as VSD, patent ductus
arteriosus (PDA) and patent foramen ovale, as well as malrotation
of the intestine. Although catecholamines and diuretics were used
to treat decreased urine volume and cardiac dilation, pulmonary
hypertension persisted, and increased cardiac dilation and
decreased cardiac contractility were observed. At 16 days of age,
the patient required artificial respiration with endotracheal
intubation. After extubation due to stable breathing and
circulatory dynamics at 40 days of age, nasal directional positive
airway pressure (n-DPAP) was used. However, the patient’s
respiratory condition worsened after discontinuing n-DPAP at
44 days of age, and artificial respiration with endotracheal
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intubation was again required at 50 days of age. Pulmonary artery
banding and PDA ligation were performed at 67 days of age for
severe cardiac hypofunction. After extubation at 84 days of age,
she required high-flow nasal cannula for respiratory failure for
8 days and was transferred to the general ward at 109 days of age,
although metabolic acidosis of uncertain cause was observed, and
treatment for heart failure was required. The patient showed
severe DD, generalized hypotonia and dysmorphic features,
including a flat nasal bridge and low-set ears, and was suspected
of having dilated cardiomyopathy (Table 1). Laboratory tests for
various metabolic disorders were unremarkable. Conventional
G-banded chromosome analysis showed a normal 46,XX karyo-
type. Her clinical features were not sufficient to diagnose a specific
disease but suggested potential genetic disorders, including
diseases caused by either a single gene or a chromosomal defect.
The ethics committees of Tokushima University approved this
study. After obtaining written consent from the parents of the
patient, molecular diagnosis was performed using genomic DNA
extracted from patient whole blood. TES was performed using a
TruSight One Sequencing Panel (Illumina, San Diego, CA, USA)
and a MiSeq benchtop sequencer (Illumina). The alignments of
sequencing reads to the human reference genome (GRCh37/
hg19), duplicate read removal, local realignment around indels,
base quality score recalibration, variant calling and annotation
were performed as previously described.12 To identify SNVs, we
excluded sequence variants with minor allele frequencies
(40.05) included in various human genome variation databases,
as previously described,13 and used an integrative Japanese
Genome Variation Database ( https://ijgvd.megabank.tohoku.ac.
jp/). Detection of CNVs using TES data with a resolution of a
single exon to several exons, depending on the size of exons,
was performed as previously described13 and using an eXome-
Hidden Markov Model v1.0 (XHMM, https://atgu.mgh.harvard.
edu/xhmm/). These analyses showed no disease-causing SNVs or
indels, but detected monoallelic deletions of 10 genes (including
the gene SKI (OMIM 164780), which may contribute to the 1p36
deletion phenotype)14 located from positions 957,571 to
3,649,301 on chromosome 1 (1p36.33-p36.32), suggesting
the presence of a gross chromosomal deletion involving the
1p36.3 region (Figure 1a). Validation and fine mapping
of the deleted region were performed by CMA using an
Affymetrix CytoScan HD chromosome microarray platform
(Affymetrix, Santa Clara, CA, USA), as previously described,15
and fluorescence in situ hybridization (FISH) using probes for the
commonly deleted region (CDC2L1) and the subtelomeric region
(CEB108/T7, maximal physical distance from telomereo300 kb).
Although no probes were located within ~ 850 kb of the terminal
region of 1p36.33 in the Affymetrix CytoScan HD array, CMA
detected a monoallelic chromosomal deletion within 1p36.32-
p36.33 as 46,XX.arr[hg19] 1p36.33-p36.32(849,466–4,034,097)x1
(Figure 1b). FISH detected the deletion of probes for CDC2L1 and
CEB108/T7, suggesting that a pure terminal deletion occurred at
1p36.3-pter (data not shown). The FISH-based karyotype was
46,XX.ish del(1)(p36)(CEB108/T7-,CDC2L1-). The deletion was
not confirmed as de novo because of the unavailability of
parental DNA.
Using the NGS-first approach, a disease-causing CNV in 1p36
was identified in the undiagnosed patient who lacked distinctive
signs and symptoms, particularly typical craniofacial features, of
chromosome 1p36 deletion syndrome (Table 1). At the time of
clinical evaluation, the patient was likely too young to be
recognized as having the clinical features of chromosome 1p36
deletion syndrome. The sequencing panel used in this study was
constructed for clinical use to detect disease-causing SNVs, and
targets in ~ 12-Mb regions covering ~ 5,000 genes associated with
known clinical phenotypes based on Online Mendelian Inheri-
tance in Man (OMIM; http://www.omim.org/). Therefore, the
targeted regions of this panel represented ~ 20 % of the entire
exome and 0.4 % of the genome. The potential clinical relevance
of CNV increases with respect to the number of genes, particularly
morbid OMIM genes, genes important in development or genes
having a dosage phenotypic effect, within the region of genomic
imbalance.9 Therefore, the TES data extracted from this sparse
panel may be sufficient to simultaneously evaluate disease-
causing SNVs and CNVs in first-choice diagnostic approaches for
undiagnosed congenital diseases that are suspected of being
genetic in origin. With respect to the interpretation of CNVs, the
sequence-first approach using this panel has an advantage
because those observed by TES using this panel may be
designated as disease causing if CNVs are detected only in
affected individuals. After WES or TES analysis, CMA with or
without FISH is also necessary to accurately determine the range
of the region of genomic imbalance for accurate cytogenetic
Table 1. Summary of clinical features frequently observed in patients
with chromosome 1p36 deletion syndrome7 and the present case
Characteristics Present case Frequenciesa
Age at clinical evaluation 4 months 0–25 years
Craniofacial and skeletal features
Characteristic craniofacial features
Microcephaly − 83 % (20/24)
Brachycephaly − 65 % (11/17)
Straight eyebrow − 84 % (32/38)
Deep-set eyes − 93 % (37/40)
Epicanthus − 86 % (30/35)
Broad nasal root/bridge + 97 % (32/33)
Long philtrum ± 63 % (22/35)
Low-set ears + 88 % (29/33)
Pointed chin − 89 % (34/38)
Late closure of the anterior fontanel NA 56 % (18/32)
Neurological features (clinical)
Axial hypotonia + 92 % (44/48)
Poor sucking ± 70 % (32/46)
Difficulty in swallowing − 56 % (27/48)
Developmental delay
Intellectual disability NA 98 % (49/50)
Acquire independent gait NA 32 % (16/50)
Behavior disorders
Self-injury NA 30 % (11/37)
Temper tantrum NA 30 % (11/37)
Epilepsy
History of epilepsy − 70 % (35/50)
Neurological features (radiological)
Cerebral white matter
Enlargement of lateral ventriclesb + 36 % (15/42)
Cardiac abnormalities
Congenital heart defects
PDA + 37 % (18/49)
VSD + 37 % (18/49)
Sensory organs
Ears
Hearing problems Mild 39 % (19/49)
Eyes
Strabismus − 33 % (15/46)
Abbreviations: NA, not available; PDA, patent ductus arteriosus; VSD,
ventricular septal defects. aFrequency of each clinical feature reported by
Shimada et al.7 was shown. Only clinical features reported with high
frequency (more than 30 %) were listed. bEnlargement of lateral ventricles
was detected by computed tomography at 5 months of age and magnetic
resonance imaging at 8 months of age.
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diagnosis, estimation of prognosis, appropriate treatment and
genetic counseling for patients, although no correlation between
deletion size and the number of observed clinical features was
reported in a large cohort of chromosome 1p36 deletion
syndrome.16
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Figure 1. (a) eXome-Hidden Markov Model (XHMM) analysis using targeted-exome sequencing (TES) data automatically detected the genomic
copy number loss of 10 genes (blue bars) located within 1p36.33-p36.32, suggesting a 2.7-Mb deletion (purple closed arrow). The x axis shows
the physical position, and the y axis shows the Z score of the principal component analysis (PCA) that was normalized to read depth. Purple
circles connected by red lines represent values of the individual subjected to TES. Gray dots with gray connected lines indicate the results of
normalized read depth obtained from in-house control data (N= 106). Copy number gains (green dots) and losses (red dots) of target sites on
the CDK11A gene were detected in three and four control samples, respectively. (b) Chromosomal microarray (CMA) using an Affymetrix
Cytoscan HD array demonstrated a 3.2-Mb heterozygous deletion within 1p36.33-p36.32 (red closed arrow). The weighted-copy number log2
ratio, allele peak spots and genes included in Trusight One (blue bars) are shown. Because of the lack of probes in the 850-kb terminal region
of 1p36.33 (black closed arrow), additional fluorescence in situ hybridization (FISH) analysis using a subtelomere probe was required to
demonstrate the 1p36 terminal deletion. Compared with TES-based copy number variation (CNV) detection, the distal and proximal break
points of the deleted region were shifted to the distal and proximal sides, respectively, in CMA (purple closed arrow).
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